Skip to main content
. 2018 Feb 27;77(5):374–382. doi: 10.1093/jnen/nly014

TABLE 1.

INSM1 Immunostaining in CNS Neoplasms

Diagnosis Total (%) Diffuse (%) Patchy (%) Rare (%)
Medulloblastoma (n = 94) 82 (87%) 22 (23%) 43 (46%) 17 (18%)
Atypical teratoid/rhabdoid tumor (n = 9) 1 (11%) 0 (0%) 0 (0%) 1 (11%)
Pineal parenchymal tumor (n = 28) 12 (43%) 1 (4%) 6 (21%) 4 (14%)
CNS embryonal, other (n = 14) 6 (43%) 0 (0%) 2 (14%) 4 (29%)
Central neurocytoma (n = 11) 11 (100%) 7 (64%) 4 (36%) 0 (0%)
Pituitary adenoma (n = 10) 10 (100%) 7 (70%) 3 (30%) 0 (0%)
Ganglioglioma (n = 14) 1 (7%) 0 (0%) 0 (0%) 1 (7%)
Ependymoma (n = 62) 3 (5%) 0 (0%) 0 (0%) 3 (5%)
Pleomorphic xanthoastrocytoma (n = 8) 1 (13%) 0 (0%) 0 (0%) 1 (13%)
Pilocytic astrocytoma (n = 43) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Diffuse astrocytoma (n = 29) 6 (21%) 0 (0%) 0 (0%) 6 (21%)
Glioblastoma (n = 94) 41 (44%) 1 (1%) 10 (11%) 30 (32%)
Total (n = 416) 174 (42%) 38 (9%) 68 (16%) 67 (16%)